Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW095103474Aexternal-prioritypatent/TWI310038B/en
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Publication of DOP2006000183ApublicationCriticalpatent/DOP2006000183A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La invención proporciona variantes del péptido PYY 3-36 y sus derivados pegilados y composiciones y métodos útiles en el tratamiento de estados modulares por el agonista del recetor Y2 del neuropeptido Y (NPY).The invention provides variants of the PYY 3-36 peptide and its pegylated derivatives and compositions and methods useful in the treatment of modular states by the neuropeptide Y2 receptor agonist Y (NPY).
DO2006000183A2006-01-272006-08-03
PPY AGONISTS AND THEIR USES
DOP2006000183A
(en)
Compound derived from 2-arylamino-4- (heterocycle) aminopyrimidine, c-alpha protein kinase inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of diabetes, cancer, coronary heart disease, atherosclerosis, among others.
Compounds derived from substituted aromatic heterobicycles, py3 kinase inhibitors; pharmaceutical composition; Useful in the treatment of cancer, melanomas, glioblastomas, among other diseases.
COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
Pyridine derived compounds; preparation procedure; pharmaceutical composition of said compounds; and use in the treatment and / or prophylaxis of type I and / or type II diabetes mellitus.
Compound derived from 2-arylamino-4-aminopyrimidines, c-alpha protein kinase inhibitors; pharmaceutical compositions containing them; and its use to treat or prevent diabetes, cancer, cardiovascular diseases and others.